Health care for people with sickle cell disease in a medium-sized Brazilian city

Health care for people with sickle cell disease

Rosana Paula Pires1, Mário Cézar de Oliveira1\*, Lucio Borges de Araújo2, João Carlos de Oliveira3, Tânia Machado de Alcântara4

1Transfusion Agency, Hospital de Clínicas de Uberlândia, Uberlândia, Minas Gerais, Brazil.

2Faculty of Mathematics, Federal University of Uberlândia, Uberlândia, Minas Gerais, Brazil.

3Technical School of Health, Federal University of Uberlândia, Uberlândia, Minas Gerais, Brazil.

4Pathology Laboratory, Hospital de Clínicas de Uberlândia, Uberlândia, Minas Gerais, Brazil.

\*Corresponding author: Mário Cézar de Oliveira, Pará Avenue, 1720, Umuarama, Uberlândia, Minas Gerais, Brazil. Postal Code: 38405-320. Phone number: 5534992615525. E-mail address: [mario.oliveira@ufu.br](mailto:mario.oliveira@ufu.br).

**Abstract**

The objective of the study was to evaluate the access, assistance and satisfaction of people with sickle cell disease in relation to the health care provided by the Unified Health System in the Uberlândia city, Minas Gerais, Brazil. Thirty-four people with sickle cell disease were recruited using the snowball sampling method and submitted to semi-structured interview, with collection of demographic, clinical and relationship data and satisfaction with health care. Forty-four percent were not included in the Primary Health Care network, which did not provide several procedures/actions recommended by the Ministry of Health. Ninety-four percent were unsatisfied/partially satisfied with the emergency care provided in the Integrated Care Units. The main reasons for this unsatisfied were ignorance of sickle cell disease by the health team (87.5%), delay in care (81.3%) and inadequate conduct by the health team (59.5%). In conclusion, the access and quality of care provided to people with sickle cell disease by the Primary Health Care network and the Urgency and Emergency Network need to be improved and this improvement is directly related to the training of health teams.

**Keyworks**: Sickle Cell Disease, Primary Health Care, Evaluation of Health Care.

**Introduction**

Sickle cell disease (SCD) is one of the most prevalent monogenic hereditary diseases in Brazil and worldwide, being considered an important public health problem [1-3]. Originally from Africa, it was brought to Brazil by the forced migration of slaves, most often affecting black and brown people. According to the National Neonatal Screening Program, it is estimated that 3,500 children with SCD and 200,000 with sickle cell trait are born in Brazil each year [4,5].

Transmitted in an autosomal recessive pattern, SCD results from a mutation in the beta-globin gene, with the formation of an anomalous hemoglobin called hemoglobin S (HbS). In addition, SCD encompasses a group of hemoglobinopathies in which the HbS gene is present in homozygosis (SS genotype) or in compound heterozygosis, that is combined with another hemoglobin variant such as hemoglobin C (SC genotype), β-thalassemia (Sβ genotypes), hemoglobin E (SE genotype) and others rarer. The SS genotype has a more severe clinical significance, being called sickle cell anemia (SCA) [6-8].

The HbS has altered physical and chemical properties, showing a propensity to undergo polymerization under conditions of low oxygen tension, which leads to alteration of the shape of the red blood cell (sickling). Sickle red blood cells present several changes in their membrane, becoming rigid, more mechanically fragile, therefore, more susceptible to intravascular hemolysis and with increased adhesion to endothelial cells, leukocytes and platelets. Thus, they are easily trapped in places where the microcirculation is slower, generating acute vaso-occlusive events with ischemic and reperfusion injuries in various organs and tissues [9,10].

The most relevant clinical events of the disease are acute and recurrent crises of pain, chronic hemolytic anemia, progressive impairment and insufficiency of multiple organs. These manifestations, despite varying from individual to individual, are potentially devastating and, in general, have important repercussions in various aspects of a person's life, including leading to a reduction in life expectancy [11-14]. Thus, as a chronic disease, which persists throughout life, usually incurable, but treatable, SCD causes its carrier to require careful and continuous assistance by a multidisciplinary health team. This assistance, when properly performed, promotes a reduction in morbidity and mortality, with an improvement in the quality of life and an increase in life expectancy [15-17].

In order to ensure that the person with SCD has adequate access, reception and assistance in the health services that are part of the Unified Health System (UHS), the Ministry of Health of Brazil published several ordinances that defined the guidelines of the National Policy for Comprehensive Care for People with Sickle Cell Disease [18]. These guidelines include diagnostic, prophylactic, propaedeutic and therapeutic actions. It was postulated that the Primary Health Care Network (PHCN) should be the preferred gateway for people with SCD in to the health system, with the Family Health Strategy (FHS) team as the organizing center for all services in all assistance levels (low, medium and high complexity). Basic Health Care (BHC) units must be integrated with the specialized care reference centers and coordinate the necessary care. Various clinical protocols and therapeutic guidelines were also developed to qualify this care and it was determined that, at all levels of care, the qualification and continuing education of health professionals involved in this care should be promoted [19-22].

This study aimed to assess the access, assistance and satisfaction of people with SCD in relation to health care provided by the UHS network in the Uberlândia city, Minas Gerais, Brazil.

**Materials and Methods**

This is a descriptive, cross-sectional, quali-quantitative study, in which people with SCD who lived in the Uberlândia city participated.

Uberlândia city is located in the southeast of the country, being the second city in population in the Minas Gerais state in Brazil, which was estimated by the Brazilian Institute of Geography and Statistics in 2019, at 691,305 inhabitants [23]. According to a report made available by the website of the National Register of Health Establishments [24], the Public Health network of Uberlândia city that provides services to UHS, has 56 Family Health Teams (FHT), 12 conventional Basic Health Units (BHU), 8 Integrated Care Units (ICU), an university hospital (belonging to the Federal University of Uberlândia) and a Blood Center (belonging to the Hemominas Foundation), providing assistance at the level of primary care and medium and high complexity.

Participants were recruited using the snowball sampling technique [25]. In summary, a key-informant was found, that is, a known person with a SCD. This person was asked to indicate the contact of other people who also had the disease. The process continued until the minimum sample size was reached and slightly exceeded.

To determine the sample size, the methodology proposed by Fonseca & Martins was used [26]. Knowing that the population of Uberlândia city in the age group of 18 to 54 years is approximately 400,000 people [23], that the incidence rate of SCD in Minas Gerais state is around 1:1400 live births [27] and that a sampling precision of 1% around the central value and a 95% confidence level were desired, it was calculated that the minimum sample size should be 27 participants.

Thirty-four people with SCD participated in the study, who met the inclusion criteria: being 18 years of age or older, living in Uberlândia city and not having cognitive impairment or having other relevant chronic diseases not related to SCD. All of them had a diagnosis of SCD confirmed by the hemoglobin electrophoresis test, performed previously at some time in their lives, whose result (genotype) was in the data in the Blood Center’s registry. After signing a free and informed consent form, they were submitted to a semi-structured interview, with collection of demographic, clinical and relationship data and satisfaction with healthcare. The interviews were conducted from November 2018 to January 2019.

The data obtained were recorded in an electronic data base in Microsoft Excel and submitted to an exploratory descriptive statistical analysis (frequencies and percentages for categorical variables and measures of central tendency and dispersion for continuous variables). All analyzes were performed using SPSS 20 software.

All experimental procedures were approved by Research Ethics Committee (CEP) of the Federal University of Uberlândia, with protocol number 2.985.296.

**Results**

The thirty-four participants were aged between 18 to 70 years old, with an average age of 35.82 ± 15.29 years old. Only one (2.9%) was 70 years old and about 65% was 40 years old or younger. Regarding gender, there was a small predominance of males, which corresponded to 55.9% of the sample. The majority (79.4%) had black or brown skin (Table 1). Eighteen individuals (53.9%) had completed high school. Of these, five (14.7%) were in higher education and one (2.9%) had already completed it. Eleven people (32.4%) had only elementary education and of these, seven (20.6%) did not complete it.

The most common hemoglobin genotype was SS (64.7%) and eight people (23.5%) had their diagnosis established by neonatal screening (Foot Test). Thirty-three (97.1%) had already been hospitalized due to complications related to SCD. Fifteen participants (44.1%) used hydroxyurea (Table 1).

Regarding access and use of the health system, 15 participants (44.1%) were not included in the Primary Health Care network as a result of living in areas without coverage. This contrasted with the monitoring at the Specialized Service, carried out by the Regional Blood Center of Uberlândia, in which 32 people (94.1%) were followed up. The 19 participants (55.9%) inserted in the BHC were questioned regarding the availability by this network of the procedures and actions recommended by the Ministry of Health (Table 2).

Emergency care is provided by ICU and when asked about satisfaction with this service, only two participants (5.9%) were satisfied, 20 (58.8%) were unsatisfied and 12 (35.3%) partially satisfied (Table 3). The main reasons spontaneously reported for this unsatisfied/partial satisfaction were, in decreasing order, ignorance of SCD by the health team, delay in service and inadequate conduct by the service team (Table 4).

Between 32 participants accompanied by the Specialized Service, 24 (75%) are satisfied with this service and eight (25%) partially satisfied (Table 3). The partially satisfied ones complained of difficulty in understanding the language used in the orientation (33.3%), unpreparedness of the physiotherapy team (22.2%) and precarious resources for dental treatment (11.1%) (Table 5).

**Discussion**

Our study included only people with SCD aged 18 years old or over, who did not have cognitive deficits. These two criteria associated with the fact that most of them (53.9%) had completed high school suggest that the reports and opinions they issue are consistent with the realities experienced.

The slight predominance of the male gender was also observed in the study by Fernandes et al. [28], in which 52.8% of children hospitalized with SCD were of the same gender. Some studies show a higher prevalence of females [29,30]. These findings together reinforce the fact that SCD is a genetic disease not linked to sex. The highest frequency of the SS genotype (sickle cell anemia) among the participants is in line with the fact that it is the most frequent worldwide [7]. Similarly, confirming what is already observed worldwide, a greater number of blacks and browns affected by the disease were also found. This finding is relevant to the extent that this population group has, in general, the worst epidemiological, educational and economic indicators, which contributes to a worse prognosis of the disease [11,31].

Interestingly, the meeting of seven people (20.6%) aged between 50 and 70 years old and among these, three of them considered elderly, that is, aged 60 years old or over. This is not a very common finding in SCD. In a study that evaluated 3,764 people with SCD, that the median age at the time of death for patients with the SS genotype was 42 years for men and 48 years for women and 60 years for men and 68 years for women with SC genotype [32]. These data corroborate our findings, since the three elderly individuals had the SC genotype.

All participants, except one, had already been hospitalized. This single exception corresponded to the 70 year old individual with the SC genotype and can be explained by the clinical variability of the disease. This variability can be associated with genetic factors, such as genotype and environmental factors, such as socioeconomic status, place of residence, access and quality of medical care and prevalence of infectious diseases [15].

In Minas Gerais state, the State Neonatal Screening Program (Foot Test) implemented screening for hemoglobinopathies in March 1998, so it has been 21 years in relation to this study. In recent years, 98% of newborns in Minas Gerais state have neonatal screening. The objective of this program, in addition to the early diagnosis of SCD, the institution of adequate treatment and prophylactic measures that contribute to a significant reduction in morbidity and mortality [33]. In our study, 75% of participants aged between 18 to 21 years old had their diagnosis confirmed by this procedure, reflecting the initial results of implementing the program in the Uberlândia city.

Hydroxyurea is a chemotherapeutic agent, myelosuppressant, according to some research it is currently the only drug with proven efficacy in the treatment of SCD. Some of the benefits resulting from the use of hydroxyurea in SCD are reduced frequency of painful episodes, reduced transfusion needs and episodes of acute chest syndrome, increased production of fetal hemoglobin (HbF) and decreased risk of death. Possible adverse effects from its use include neutropenia, bone marrow suppression, elevated liver enzymes, anorexia, nausea, vomiting and infertility [34,35].

In our study, about 44% of participants were using hydroxyurea. Between these participants, 80% had the SS genotype and the others the SC genotype. This finding is justified since the clinical severity of SCD in patients with the SS genotype (sickle cell anemia) is generally greater [15,36] and the prescription of hydroxyurea follow the mandatory presence of some inclusion criteria. Among these is the occurrence, in the last 12 months, of at least one of a list of complications such as: three or more acute pain episodes requiring medical attention, more than one event of acute chest syndrome, chronic hypoxemia, chronic organ injury proven, Hb < 7g/dL out of acute event, HbF concentration < 8% after 2 years old, leukocyte count > 20,000/mm3, lactic dehydrogenase levels twice above the reference value for age and changes in transcranial echocardiography [37]. This means that at least 44% of the survey participants had at least one of these complications.

Accessibility to health care can be understood as the ability to generate services and meet the health demands for a given group, including the characteristics of services and resources that facilitate or hinder their use by users. Therefore, access to a health service or service network is influenced by multiple factors such as geographic, organizational, socio-cultural and economic [38].

What we perceive in the present study is that the access of people with SCD to the Primary Health Care network in the Uberlândia city is seriously compromised, since a significant portion of the study participants (44.1%) is not included in this network in due, among other reasons, to living in places without coverage. On the other hand, we found that 94.1% of the studied population is served by the Specialized Service, represented by the Blood Center, regardless of whether they live at a reasonable distance from this institution. This picture is not new, repeating what was observed in other studies carried out in various parts of the country. One of the reasons postulated for this is that historically the treatment of SCD is perceived as the competence of hematological centers [11,39].

Perceptibly, there are other reasons for this to happen, which is evident when we analyze satisfaction with the services provided by BHC and the Blood Center. The number of unsatisfied/partially satisfied with the assistance provided by BHC was very expressive (94.1%), in contrast to the also expressive satisfaction (75.0%) shown in relation to the Blood Center. Spontaneous reporting of reasons for unsatisfied/partial satisfaction allows for a better understanding of the care situation as a whole. The most frequent complaints, in relation specifically to the emergency care provided by ICU, and the reports in the literature refer us to some possible basic reasons for these occurrences: failure in the process of humanization of the service and unpreparedness of the health teams to care for the person with SCD. This unpreparedness is undoubtedly the result of the lack of training of health teams, which perpetuates the status of ignorance of the disease and significantly limits the possibility of providing comprehensive and adequate assistance to people with SCD.

The manual “Sickle Cell Disease - Basic Guidelines for the Care Line”, prepared by the Ministry of Health [18], postulates that humanization must be based on providing a comfortable environment for the care of people. These must be received in a caring and supportive manner, without showing prejudices and stigmas; they must be listened to attentively and when dialoguing with them, respectful and accessible language to the lay public should be used. Classically, people with SCD have recurrent and disabling pain episodes. Worldwide, there are numerous publications with reports of stigmatization of adults with SCD in the health system, as health professionals are generally insensitive to their experience of pain. People with SCD are often seen by the health team as drug addicts. These negative experiences with health care make many of these people delay the search for medical care managing their episodes of pain at home. Therefore, having prior guidance to be able to perceive and understand the pain experience of the person with SCD and to properly welcome them is the first step to improve access and assistance to this population [13,40].

The second most frequent complaint, of the study participants, referred to the delay in attending when they sought the emergency service of ICU. This fact should not occur, as the investigation and recognition of warning signs in patients with SCD, makes their care a priority. This suggests that health teams were unaware of these signs and the need to prioritize care when they are present [38,39,41]. It should be noted that the participants themselves detected this ignorance of SCD by the health team. This was the main reason cited by them for their dissatisfaction with emergency care and if they were responsible for inadequate treatment.

As previously mentioned, economic and organizational factors also influence the access and efficiency of a health service [39]. Perhaps these two factors were preponderant in determining the findings regarding the availability of procedures/actions (recommended by the Ministry of Health) in Basic Health Unit and Basic Family Health Unit (BFHU). Procedures/actions such as: informing the user that the network provides hemoglobin electrophoresis test for relatives and partner, promoting the maintenance of the bond through regular visits, providing guidance on the sickle cell trait and the disease, performing the preventing wounds, identifying and forwarding urgencies/emergencies, which are not being carried out or carried out minimally, probably depend more on organizational procedures and training of the health team than economic factors. These procedures/actions are relevant, as they change attitudes and decrease physical, emotional and social problems resulting from the disease [15,39,42].

A limitation of our study is due to the sampling method used (snowball sampling method), which may have led to the constitution of a sample that is not so representative of the population of people with SCD in the Uberlândia city.

**Conclusions**

When evaluating the public health assistance provided in the Uberlândia city to people with sickle cell disease, from their perspective, it is clear that both the access and the quality of care provided by BHU, BFHU and ICU need to be improved. And this improvement is undoubtedly directly related to the training of health teams.

We hope that this study can contribute to raising the awareness of state and municipal health managers to make efforts to provide continuing education in sickle cell disease to their health teams, which results in transformative actions and, thus, they can fulfill their role of providing comprehensive and quality health care.

**Author contributions**

RPP conceived the idea. RPP performed data collect. RPP, JCO and TMA performed analyzed the data. TMA and LBA contributed with statistical analysis. RPP, MCO, JCO and TMA wrote the manuscript.

**Funding source**

Not applicable

**Conflicts of interest**

The authors declare that they have no conflict of interest.

**Reference**

1. Pires RP, Rocha AF. Assistência de Enfermagem a Trabalhadores Portadores de Doença Falciforme. Rev Bras Hematol Hemoter 2009; 31:36-46.

2. Lobo C. Doença falciforme - um grave problema de saúde pública mundial. Rev Bras Hematol Hemoter 2010; 32:280-1.

3. Pule GD, Mnika K, Joubert M, Mowla S, Novitzky N, Wonkam A. Burden, genotype and phenotype profiles of adult patients with sickle cell disease in Cape Town, South Africa. SAMJ 2017; 107:149-55.

4. Cançado RD, Jesus JA. A doença falciforme no Brasil. Rev Bras Hematol Hemoter 2007; 29:203-6.

5. Martins PRJ, Moraes-Souza H, Silveira TB. Morbimortalidade em doença falciforme. Rev Bras Hematol Hemoter 2010; 32:378-83.

6. Naoum PC, Bnoninii-Domingos CR. Doença falciforme no Brasil. Origem, genótipos, haplótipos e distribuição geográfica. J Bras Patol Med Lab 1997; 33:145-53.

7. Saraf SL, Molokie RE, Nouraie M, Sable CA, Luchtman-Jones L, Ensing GJ, et al. Differences in the clinical and genotypic presentation of sickle cell disease around the world. Paediatr Respir Rev 2014; 15:4-12.

8. Habara A, Steinberg MH. Genetic basis of heterogeneity and severity in sickle cell disease. Exp Biol Med 2016; 241:689-96.

9. Manwani D, Frenette PS. Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies. Blood 2013; 122: 3892-8.

10. Sundd P, Gladwin MT, Novelli EM. Pathophysiology of Sickle Cell Disease. Annu Rev Pathol 2019; 14: 263-92.

11. Kikuchi BA. Assistência de enfermagem na doença falciforme nos serviços de atenção básica. Rev Bras Hematol Hemoter 2007; 29:331-8.

12. Lervolino LG, Baldin PEA, Picado SM, Calil KB, Viel AA, Campos LAF. Prevalence of sickle cell disease and sickle cell trait in national neonatal screening studies. Rev Bras Hematol Hemoter 2010; 33:49-54.

13. Evensen CT, Treadwell MJ, Keller S, Levine R, Hassell KL, Werner EM, et al. Quality of Care in Sickle Cell Disease: Cross-sectional study and development of a measure for adults reporting on ambulatory and emergency department care. Medicine 2016; 95:1-7.

14. Maitra P, Caughey M, Robinson L, Desai PC, Jones S, Nouraie M, et al. Risk factors for mortality in adult patients with sickle cell disease: a meta-analysis of studies in North America and Europe. Haematologica 2017; 102:626-36.

15. Zago MA, Pinto ACS. Fisiopatologia das doenças falciformes: da mutação genética à insuficiência de múltiplos órgãos. Rev Bras Hematol Hemoter 2007; 29:207-14.

16. Brunetta DM, Clé DV, Haes TM, Roriz-Filho JS, Moriguti JC. Manejo das complicações agudas da doença falciforme. Medicina (Ribeirão Preto) 2010; 43:231-7.

17. Strouse J. Sickle cell disease. Handb Clin Neurol 2016; 38:311-24.

18. Brasil. 2005. Ministério da Saúde. Portaria GM/MS no 1.391. Diário Oficial da União, Poder Executivo, Brasília, DF. 159, 1: 40.

19. Brasil. 2009. Ministério da Saúde. Portaria MS/GM no 2.084. Diário Oficial da União, Poder Executivo, Brasília, DF. 1: 61.

20. Brasil. 2010. Ministério da Saúde. Portaria SAS n 55. Diário Oficial da União, Poder Executivo, Brasília, DF. 1: 69-71.

21. Brasil. 2012. Ministério da Saúde. Secretaria de Atenção à Saúde. Departamento de Atenção Especializada. Doença falciforme: condutas básicas para tratamento. Brasília. 64.

22. Brasil. 2015. Ministério da Saúde. Secretaria de Atenção à Saúde. Departamento de Atenção Hospitalar e de Urgência. Doença falciforme: diretrizes básicas da linha de cuidado. Brasília. 82.

23. IBGE. 2019. Population statistics reports for the Uberlândia MG. https://www.ibge.gov.br/cidades-e-estados/mg/uberlandia.html/ (accessed 10december 2019).

24. CNES. 2019. Public health network for the Uberlândia MG. <http://cnes.datasus.gov.br/pages/estabelecimentos/consulta.jsp?search=UBS%20DE%20UBERLANDIA%20MG/> (accessed 10 december 2019).

25. Berg S. Snowball Sampling. In: Kotz S., Johnson N.L. Encyclopedia of Statistical Sciences 1988; 8:528-32.

26. Fonseca JS, Martins GA. Curso de Estatística. 6ª ed, Ed. Atlas, 2006; 320p.

27. Januário JN. Incidência da doença falciforme em um milhão de nascidos vivos em Minas Gerais (1998-2001). Belo Horizonte (MG): Universidade Federal de Minas Gerais 2002: 97p.

28. Fernandes APPC, Avendanha FA, Viana MB. Hospitalizations of children with sickle cell disease in the Brazilian Unified Health System in the state of Minas Gerais. J Pediatr (Rio J) 2017; 93:287-93.

29. Felix AA, Souza HM, Ribeiro SBF. Aspecto clínico – Epidemiológico e percepção de dor na doença falciforme. Rev Bras Hematol Hemoter 2010; 32:203-8.

30. Cunha JHS, Monteiro CF, Ferreira LA, Cordeiro JR, Souza LMP. Papeis ocupacionais de indivíduos com anemia falciforme. Rev Ter Ocup Univ São Paulo 2017; 28:230-8.

31. Paiva e Silva RB, Ramalho AS, Cassorla RMS. A anemia falciforme como problema de Saúde Pública no Brasil. Rev Saúde Pública 1993; 27:54-8.

32. Platt OS, Brambilla DJ, Rosse EF, Milner PF, Castro O, Steinberg MH, et al. Mortality in sickle cell disease-life expectancy and risk factors for early death. N Engl J. Med 1994; 330:1639-44.

33. Rodrigues DOW, Ferreira MCB, Campos EMS, Pereira PM, Oliveira CM, Teixeira MTB. História da triagem neonatal para doença falciforme no Brasil – capítulo de Minas Gerais. Rev Med Minas Gerais 2012; 22:1-128.

34. Agrawal RK, Patel RK, Shah V, Nainiwal L, Trivedi B. Hydroxyurea in Sickle Cell Disease: Drug Review. Indian J Hematol Blood Transfus 2014; 30:91-6.

35. McGann PT, Ware RE. Hydroxyurea therapy for sickle cell anemia. Expert Opin Drug Saf 2015; 14:1749.

36. Steinberg MH, Sebastiani P. Genetic modifiers of sickle cell disease. Am J Hematol 2012; 87:795-803.

37. CONITEC. Comissão Nacional de Incorporação de Tecnologias no SUS. Protocolos Clínicos e Diretrizes Terapêuticas Doença Falciforme **–** Relatório de Recomendação 2016: 29p.

38. Gomes LM, Reis TC, Vieira MM, Andrade-Barbosa TL, Caldeira AP. Quality of assistance provided to children with sickle cell disease by primary healthcare services. Rev Bras Hematol Hemoter 2011; 33:277-82.

39. Gomes LMX, Pereira IA, Torres HC, Caldeira AP, Viana MB. Acesso e assistência à pessoa com anemia falciforme na atenção primária**.** Acta Paul Enferm 2014; 27:348-55.

40. Haywood CJr, Beach MC, Lanzkron S, Strouse JJ, Wilson R, Park H, et al. A systematic review of barriers and interventions to improve appropriate use of therapies for sickle cell disease. J Natl Med Assoc 2009; 101:1022-33.

41. Gomes LM, Vieira MM, Reis TC, Andrade-Barbosa TL, Caldeira AP. Understanding of technical education level professionals regarding sickle cell disease: a descriptive study. Online Braz J Nurs 2013; 12:482-90.

42. Araújo PIC. O autocuidado na doença falciforme. Rev Bras Hematol Hemoter 2007; 29:239-46.

**Tables**

Table 1: Demographic characteristics of the participants and use of hydroxyurea in relation to the disease genotype.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Characteristics of the participants** | **Genotype** | | | |
|  | SS (N=22)  64,7% | SC (N=11)  32,4% | Sβ (N= 1)  2,9% | Total (N=34) |
| **Sex**  Female  Male | 5 (33,3)  17 (89,5) | 9 (60,0)  2 (10,5) | 1 (6,7)  0 (0) | 15 (44,1)  19 (55,9) |
| **Skin**  Black  Brown  White | 11 (57,9)  7 (87,5)  4 (57,1) | 8 (42,1)  1 (12,5)  2 (28,6) | 0 (0)  0 (0)  1 (14,3) | 19 (55,9)  8 (23,5 )  7 (20,6) |
| **Age group (years)**  18 - 21  22 - 49  50 - 70 | 6 (60,0)  14 (82,4)  2 (28,6) | 4 (40,0)  3 (17,6)  4 (57,1) | 0(0)  0 (0)  1 (14,3) | 10 (29,4)  17 (50,0)  7 (20,6) |
| **Hydroxyurea**  No  Yes  Already used in the past | 5 (35,7)  12 (80,0)  5 (100,0) | 8 (57,2)  3 (20,0)  0 (0) | 1 (7,1)  0 (0)  0 (0) | 14 (41,2)  15 (44,1)  5 (14,7) |

Table 2: Availability in the Basic Health Units (BHU) and Basic Family Health Units (BFHU) of the procedures/actions recommended by the Ministry of Health.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Procedures/actions** | **Availability in health units (BHC and BFHU)** | | | |
|  | No  N (%) | Yes  N (%) | Do not know  N (%) | Total=19 |
| Electrophoresis Hb | 9 (47,4) | 0 (0) | 10 (52,6) |  |
| Sickle cell trait orientation | 17 (89,4) | 1 (5,3) | 1 (5,3) |  |
| Forwarding of exams requested  by the specialized service | 4 (21,1) | 15 (78,9)\* | 0 (0) |  |
| Supply of medications protocol | 16 (84,2) | 3 (15,8)**\*\*** | 0 (0) |  |
| Supply of vaccines protocol | 0 (0) | 19 (100) | 0 (0) |  |
| Wound prevention and forwarding  to a referral center | 12 (63,2) | 0 (0) | 7 (36,8) |  |
| Link maintenance | 17 (89,5) | 2 (10,5) | 0 (0) |  |
| Identification and forwarding of urgencies/emergencies | 19 (100) | 0 (0) | 0 (0) |  |
| Promotion of social inclusion | 17 (89,5) | 0 (0) | 2 (10,5) |  |

\* About 80% of patients who stated that BHC conducts the examinations requested by the Specialized Service also reported that they enter a waiting list with an average delay of 2 years for the examinations.

\*\* The units' pharmacies only supply medicines when they are made available by the municipality, which is not always the case.

Table 3: Satisfaction of study participants with urgent/emergency care in Integrated Care Units (ICU) and Specialized Service (Hemocentro).

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Service** | **Satisfaction** | | | |
| Integrated Care Units (ICU) | Unsatisfied  N (%) | Satisfied  N (%) | Partially satisfied  N (%) | N=34 |
| 20 (58,8) | 2 (5,9) | 12 (35,3) |
|  |  |  |  |  |
| Specialized Service (HEMOCENTRO) | Unsatisfied  N (%) | Satisfied  N (%) | Partially satisfied  N (%) | N=32 |
| 0 (0) | 24 (75,0) | 8 (25,0) |

Table 4: Main reasons for unsatisfied/partially satisfied of 32 study participants in relation to emergency care in Integrated Care Units (ICU).

|  |  |
| --- | --- |
| **Reasons for unsatisfied/partially satisfied** | **N (%)** |
| Not knowledge of sickle cell disease by the health team | 28 (87,5) |
| Service delay | 26 (81,3) |
| Inappropriate conduct by the health team | 19 (59,5) |
| Lack of unit structure | 15 (46,9) |

Table 5: Main reasons for the partial satisfaction of eight study participants in relation to attendance at the Specialized Service (Hemocentro).

|  |  |
| --- | --- |
| **Reasons for partially satisfied** | **N (%)** |
| Difficulty understanding the language used in orientation | 26 (33,3) |
| Lack of preparation of the physiotherapy team | 15 (22) |
| Precarious resources for dental treatment | 19 (59,5) |